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background:  Rivaroxaban is a novel direct factor Xa inhibitor approved for multiple indications. As part of an FDA post-marketing safety 
requirement, a five-year observational study was designed to evaluate major bleeding (MB) among non-valvular atrial fibrillation (NVAF) 
patients on rivaroxaban.
Methods:  Using a validated database method (Cunningham algorithm), 9.7 million electronic medical records from the Department of 
Defense healthcare system were queried to identify MB-related hospitalizations among rivaroxaban users with NVAF. MB mainly included 
gastrointestinal bleeding, hemorrhagic strokes and other intracranial bleeds, and genitourinary bleeding. Additional data were collected 
on fatal outcomes, surgical interventions and transfusions. Demographics, comorbidities, risk factors, and MB management were also 
evaluated.
results:  In the first 18 months of the study, 31,833 rivaroxaban patients were identified. Of these, 622 experienced at least one MB event; 
incidence rate of 2.85 per 100 person-years [95% CI 2.63-3.08]. Those with MB were older, with a mean (SD) age of 78.7 (7.8) versus 75.8 
(9.8) years for non-MB patients. In the MB group, the sex distribution was balanced (50.5% male) compared to the non-MB group (55.6% 
male). Comorbidities were more prevalent in MB than non-MB patients. The most common were hypertension and coronary artery disease, 
occurring in 94.1% and 72.1% in those with MB versus 62.5% and 34.4% in non-MB patients. The mean CHADS2 and CHA2DS2-Vasc 
scores among MB patients were 2.9 (1.2) and 4.8 (1.5) respectively, compared to 2.1(1.3) and 3.6 (1.6) in the non-MB patients. The most 
common MB site was gastrointestinal (88.3%), then intracranial (7.7%). About 37.3% received blood transfusions, and most MB patients 
were discharged home (73.8%). Twenty MB patients died during hospitalization at an average age of 82.1 (6.2) years, yielding a fatal MB 
rate of 0.09 per 100 person-years [95% CI 0.04-0.15]. Case fatality rate was higher for intracranial (29.2%, 14 of 48) versus gastrointestinal 
(1.1%, 6 of 549) bleeds.
Conclusion:  The MB incidence rate among rivaroxaban users with NVAF is low in a post-market setting, and generally similar to the 
registration trial.
